Last updated: April 23, 2026
Who Supplies Cilostazol to the Pharmaceutical Market?
Cilostazol is an established, generic oral antiplatelet (CAS 76619-94-2). The supply chain breaks into two layers: (1) API (active pharmaceutical ingredient) manufacture and (2) finished-dose product (FPP) manufacturing and distribution by brand and generic companies across jurisdictions. Cilostazol is widely sourced, with documented manufacturing and marketing footprints in Asia (notably China), and distribution via local wholesalers and FPP licensors worldwide.
Which companies supply cilostazol APIs (active pharmaceutical ingredient)?
The cilostazol API supplier universe is dominated by Chinese chemical and API manufacturers, with additional participation from other Asian suppliers. API availability typically comes in multiple grades (pharmaceutical grade), packaged for DMF-supported registrations in target countries.
Common API supplier archetypes in cilostazol:
- Chinese API manufacturers with DMF/CEP-linked dossiers for global filings
- Generic API trading groups that repackage and supply APIs sourced from one or more API plants
- Specialty intermediates manufacturers that feed API production chains (less visible as direct API “suppliers” in tenders)
Market-facing reality: most procurement channels treat “API suppliers” as either (a) registered dossier holders or (b) tenders/quotations listing the deliverable API manufacturer, with the dossier holder naming controlled by the filing geography.
Which companies supply cilostazol finished-dose products (tablets/capsules)?
Finished-dose supply is much broader and includes:
- Original and legacy brand holders in specific geographies
- Generic FPP manufacturers producing locally approved tablets under marketing authorizations
- Contract manufacturers supplying private-label or authorized generic products through distribution partners
Because cilostazol is marketed in multiple countries, the FPP landscape changes by region (Japan, South Korea, parts of Europe, and broad availability in other markets through generics). In many markets, supply is carried by local generic manufacturers and distributors rather than a single global brand owner.
How to map cilostazol supply for procurement (API vs FPP)?
Procurement decisions depend on whether you need:
- API for formulation (API supplier with appropriate regulatory dossier support)
- Finished tablets (FPP manufacturer with local marketing authorization or authorized supply chain)
Supplier selection criteria commonly used in cilostazol sourcing:
- Regulatory dossier coverage (DMF/CEP or local equivalent filing readiness)
- Manufacturing site qualification and quality agreement terms
- Ability to provide CoA, specification sheets, impurity profile, and stability commitment
- Packaging and lead time consistency for tender or ongoing supply
What is the practical supplier set by supply-chain role?
API supply set
The active ingredient is typically supplied by:
- Direct API manufacturers in China and East Asia
- Regional distributors sourcing from one or more API plants
- Contract supply arrangements tied to dossier holders
FPP supply set
Finished products typically come from:
- Local generics manufacturers in each target country
- Authorized generics and private-label supply through distribution networks
- Contract manufacturing where marketing authorization belongs to an MA holder
Where cilostazol is marketed and distributed (evidence anchors)
Cilostazol is an approved drug product and is listed across multiple drug product compendia and national formularies. This confirms broad commercialization and ongoing manufacturing activity, even when the exact supplier list varies by country.
Reference evidence for commercialization and regulatory footprint:
- FDA Orange Book listings for cilostazol products (US marketing authorizations and therapeutic equivalence status where applicable). [1]
- EMA/European medicines databases for member-state approved medicinal products (where cilostazol is authorized). [2]
- Japanese and Korean drug listings reflect entrenched local availability and supplier ecosystems for FPP. [3,4]
Supplier diligence checklist (actionable for R&D or procurement)
A cilostazol sourcing program typically includes these operational steps:
- Confirm whether you need an API dossier holder or an approved distributor
- Validate GMP status for the actual manufacturing site
- Lock specifications: polymorph/particle attributes where relevant, impurity limits, residual solvents, and water content as per cilostazol API pharmacopeial expectations
- Require batch traceability, CoA fields, and method descriptions
- Confirm lead time and shortage history for the specific supplier and site
- Align packaging format with formulation manufacturing requirements
Key Takeaways
- Cilostazol supply splits into API manufacturers and finished-dose manufacturers/distributors, with procurement requirements differing by regulatory dossier needs.
- The API market is concentrated in Asian chemical/API manufacturing centers, with many suppliers operating through dossier-linked direct supply or distributor channels.
- The FPP market is highly fragmented by geography, with local generics and authorized generics making the practical supplier list country-specific.
- For business decisions, the actionable approach is to map suppliers by dossier holder vs distributor (API) and MA holder vs contract manufacturer (FPP), then qualify by site GMP and batch traceability requirements.
FAQs
1) Are cilostazol API suppliers the same as finished-dose suppliers?
No. API supply and finished-dose supply are typically different corporate entities and manufacturing sites, even when related companies exist in the supply chain.
2) How do I identify the correct supplier for regulatory submissions?
Use the dossier-linked party for API (DMF/CEP where applicable) and the marketing authorization holder or authorized manufacturer for finished-dose product in the target jurisdiction.
3) Is cilostazol widely available as a generic?
Yes. Cilostazol is widely commercialized as a generic across multiple markets, which drives multiple competing FPP manufacturers.
4) What supplier quality artifacts matter most for cilostazol?
Batch CoA, impurity profile, residual solvents, stability commitment (for FPP), and GMP evidence for the manufacturing site that actually makes the API or FPP.
5) Does cilostazol sourcing differ by country?
Yes. FPP supplier lists change by country due to marketing authorization coverage, tendering practices, and local distributor networks, while API sourcing often remains concentrated with multiple qualified buyers.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. Medicines database. https://www.ema.europa.eu/en/medicines
[3] Japan Pharmaceuticals and Medical Devices Agency (PMDA). Drug product information and approval records. https://www.pmda.go.jp/
[4] Ministry of Food and Drug Safety (MFDS), Republic of Korea. Drug product information and approvals. https://www.mfds.go.kr/
